Anew Labs Secures 290 Million Dollars in Funding at 1.5 Billion Dollar Valuation

Anew Labs, the artificial intelligence drug discovery division of ByteDance, completed a 290 million dollar first round of external financing on September 16, 2026, achieving a post-money valuation of 1.5 billion dollars. The company retained 56 percent of its shares while selling 44 percent to secure the capital and establish a valuation anchor. TMTPost reported the story, citing Reuters and sources familiar with the transaction. The lead investors in this round were HSG, formerly known as Sequoia China, IDG Capital, and Hillhouse Investment. Follow-on investors included 5Y Capital, Gaorong Capital, Chunhua Capital, and Boyu Capital. These domestic primary market firms provided both financial resources and networks for future funding rounds. China Biopharmaceuticals, a leading domestic pharmaceutical company with a complete clinical development and commercialization system, also participated. Its involvement offers a pathway to clinical trials and market entry, which are significantly more expensive than molecular design. The Shanghai Future Industry Fund, with a state-owned background, also invested, likely bringing local talent and policy support to the company headquartered in Shanghai. This combination of cash, valuation, and industrial resources is unprecedented among major Chinese technology companies. Baidu incubated BGI Genomics for an independent initial public offering, while Tencent focuses on investments rather than in-house drug development. The final valuation of 1.5 billion dollars exceeded the approximately 1 billion dollar estimate provided by Soochow Securities in August by about 50 percent.

This valuation is notable because the company has no clinical assets and no business development orders, with its pipeline still in the lead compound optimization stage. The value proposition rests on three layers. The outer layer is the reputation gained from open-source models. ByteDance's Seed team released the Protenix codebase in 2024, updated to version 2 in 2026 under the Apache 2.0 license. The PXDesign tool, based on this model, achieved nanomolar binding data in wet lab experiments. The middle layer is the platform matrix, including AnewOmni for molecular modeling, AnewSampling for molecular dynamics, and scNext for cell dynamics prediction. The AnewSampling team acknowledged that the scarcity of high-quality dynamic training data is the biggest bottleneck. The innermost layer is the molecule AN-5162, disclosed at the American Immunologists meeting in Boston in April. This small molecule inhibitor targets IL-17 and is in the preclinical stage. It is unique for simultaneously inhibiting IL-17AA, AF, and FF forms. The IL-17FF subtype was previously considered inaccessible to small molecules due to its structure. The pipeline also includes IL-4R and two undisclosed targets. Globally, Isomorphic Labs raised 2.1 billion dollars in May, Xaira has raised about 1.3 billion dollars, and Earendil Labs raised 787 million dollars in March. These companies also lack clinical assets. Industry statistics show that as of mid-2026, there are about 180 AI-originated drug pipelines, with only a dozen in phase three trials and zero FDA-approved AI-discovered drugs.

Insilico Medicine, the only company to advance an AI-discovered drug to phase three, raised less in its initial public offering. Its drug Rentosertib for idiopathic pulmonary fibrosis had its first patient dosed at Peking Union Medical College Hospital in September. Data shows that AI-discovered molecules have a higher pass rate in phase one trials but converge with traditional molecules in phase two. The capital invested in Anew Labs is essentially an option, with a premium for the scarcity of the IL-17FF mechanism. Anew Labs outsources all wet lab experiments to contract research organizations and uses Volcano Engine for computing power, focusing resources on algorithms and personnel rather than physical infrastructure. The company faces challenges in integrating its internal AI drug discovery lines and retaining core talent. AN-5162 is planned for an investigational new drug application submission in the fourth quarter of this year. The path from application to market approval takes years, with high clinical failure rates. The company's ability to sustain its data flywheel depends on contract research organizations cooperating with data feedback. The next major test for Anew Labs, Insilico Medicine, and Isomorphic Labs is which company first moves a molecule through clinical trials.